Waxman to seek Medicaid prices for dual eligbles
Legislation that would set Medicare Part D drug prices paid specifically for dual eligible beneficiaries at rates that were paid under Medicaid prior to being shifted to the federal prescription drug program is under development by House Oversight and Government Reform Committee Chairman Henry Waxman, D-Calif. The pending bill is an outgrowth of a report the committee released in July that said the government is paying 30 percent more for dual eligibles' drugs since drug coverage for the dual eligibles shifted from Medicaid to Medicare Part D under the Medicare Modernization Act (1"The Pink Sheet," July 28, 2008, p. 24). Brian Cohen, senior investigative counsel for the committee, said Sept. 23 during the AHIP annual Medicare and Medicaid conference that a bill could be introduced soon, but at the very latest early into the next Congress
You may also be interested in...
The Congressional Budget Office has taken proposals for a required rebate on drugs for dual-eligible beneficiaries in Medicare Part D a step further by scoring a 15 percent rebate requirement for all brand drugs in the program
House Oversight and Government Reform Committee Republicans are attempting to deflect criticism of Medicare Part D drug expenditures by redirecting focus back to larger expenditures under Parts A and B
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.